These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 32215878

  • 1. Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease.
    Skripka A, Sychev D, Bochkov P, Shevchenko R, Krupenin P, Kogay V, Listratov A, Krainyaya A, Gurinovich O, Sokolova A, Napalkov D, Fomin V.
    High Blood Press Cardiovasc Prev; 2020 Apr; 27(2):151-156. PubMed ID: 32215878
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
    Sychev D, Skripka A, Ryzhikova K, Bochkov P, Shevchenko R, Krupenin P, Ivashchenko D, Kogay V, Listratov A, Krainyaya A, Gurinovich O, Sokolova A, Napalkov D, Fomin V.
    Drug Metab Pers Ther; 2020 Mar 05; 35(1):. PubMed ID: 32134727
    [Abstract] [Full Text] [Related]

  • 5. Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation.
    Lin SY, Tang SC, Kuo CH, Tsai LK, Yeh SJ, Shen LJ, Jeng JS.
    J Formos Med Assoc; 2019 Jul 05; 118(7):1154-1160. PubMed ID: 30581104
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
    Hantrakun N, Wongcharoen W, Thiankhaw K, Norasetthada L, Tantiworawit A, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Piriyakhuntorn P, Punnachet T, Niprapan P, Chai-Adisaksopha C.
    J Thromb Thrombolysis; 2023 Feb 05; 55(2):392-398. PubMed ID: 36484957
    [Abstract] [Full Text] [Related]

  • 8. Real-world variability in dabigatran levels in patients with atrial fibrillation.
    Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis JD, Schulman S, Eikelboom JW.
    J Thromb Haemost; 2015 Mar 05; 13(3):353-9. PubMed ID: 25523236
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT, Hu YF, Liao JN, Chern CM, Lin YJ, Chang SL, Wu CH, Sung SH, Wang KL, Lu TM, Chao TF, Lo LW, Hsu LC, Chung CP, Chang PM, Hsu WH, Chiou CW, Chen SA.
    Blood Coagul Fibrinolysis; 2016 Jun 05; 27(4):389-95. PubMed ID: 26991859
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
    Korenstra J, Wijtvliet EP, Veeger NJ, Geluk CA, Bartels GL, Posma JL, Piersma-Wichers M, Van Gelder IC, Rienstra M, Tieleman RG.
    Europace; 2016 Sep 05; 18(9):1319-27. PubMed ID: 26843571
    [Abstract] [Full Text] [Related]

  • 14. Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation.
    Matsuda S, Imazu T, Kimura R, Nakamura M, Matsumoto A, Murakami T, Maeda Y.
    Ther Drug Monit; 2016 Dec 05; 38(6):670-676. PubMed ID: 27559839
    [Abstract] [Full Text] [Related]

  • 15. Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
    Fukaya H, Niwano S, Oikawa J, Nishinarita R, Horiguchi A, Nakamura H, Fujiishi T, Igarashi T, Ishizue N, Yoshizawa T, Satoh A, Kishihara J, Murakami M, Ako J.
    J Cardiol; 2017 Mar 05; 69(3):591-595. PubMed ID: 27377855
    [Abstract] [Full Text] [Related]

  • 16. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.
    Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T.
    Pharmacoepidemiol Drug Saf; 2016 Nov 05; 25(11):1236-1244. PubMed ID: 27229855
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J, Giroud M, de Pouvourville G.
    Cerebrovasc Dis; 2013 Nov 05; 35(4):320-6. PubMed ID: 23615428
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.